Please use this identifier to cite or link to this item:
https://apo.ansto.gov.au/dspace/handle/10238/9206
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Liang, SH | - |
dc.contributor.author | Southon, AG | - |
dc.contributor.author | Fraser, BH | - |
dc.contributor.author | Krause-Heuer, AM | - |
dc.contributor.author | Zhang, B | - |
dc.contributor.author | Shoup, TM | - |
dc.contributor.author | Lewis, R | - |
dc.contributor.author | Volitakis, I | - |
dc.contributor.author | Han, Y | - |
dc.contributor.author | Greguric, I | - |
dc.contributor.author | Bush, AI | - |
dc.contributor.author | Vasdev, Y | - |
dc.date.accessioned | 2020-03-23T23:53:45Z | - |
dc.date.available | 2020-03-23T23:53:45Z | - |
dc.date.issued | 2015-08-10 | - |
dc.identifier.citation | Liang, S. H., Southon, A. G., Fraser, B. H., Krause-Heuer, A. M., Zhang, B., Shoup, T. M., Lewis, R., Volitakis, I., Han, Y., Greguric, I., Bush, A. I., &. Vasdev, N. (2015). Novel fluorinated 8-hydroxyquinoline based metal ionophores for exploring the metal hypothesis of Alzheimer’s disease. ACS Medicinal Chemistry Letters, 6(9), 1025-1029. doi:10.1021/acsmedchemlett.5b00281 | en_AU |
dc.identifier.govdoc | 8803 | - |
dc.identifier.issn | 1948-5875 | - |
dc.identifier.uri | http://dx.doi.org/10.1021/acsmedchemlett.5b00281 | en_AU |
dc.identifier.uri | http://apo.ansto.gov.au/dspace/handle/10238/9206 | - |
dc.description.abstract | Zinc, copper, and iron ions are involved in amyloid-beta (Aβ) deposition and stabilization in Alzheimer’s disease (AD). Consequently, metal binding agents that prevent metal-Aβ interaction and lead to the dissolution of Aβ deposits have become well sought therapeutic and diagnostic targets. However, direct intervention between diseases and metal abnormalities has been challenging and is partially attributed to the lack of a suitable agent to determine and modify metal concentration and distribution in vivo. In the search of metal ionophores, we have identified several promising chemical entities by strategic fluorination of 8-hydroxyquinoline drugs, clioquinol, and PBT2. Compounds 15–17 and 28–30 showed exceptional metal ionophore ability (6–40-fold increase of copper uptake and >2-fold increase of zinc uptake) and inhibition of zinc induced Aβ oligomerization (EC50s < ∼5 μM). These compounds are suitable for further development as drug candidates and/or positron emission tomography (PET) biomarkers if radiolabeled with 18F. © 2015 American Chemical Society | en_AU |
dc.language.iso | en | en_AU |
dc.publisher | American Chemical Society | en_AU |
dc.subject | Reaction product transport systems | en_AU |
dc.subject | Metals | en_AU |
dc.subject | Central nervous system | en_AU |
dc.subject | Agglomeration | en_AU |
dc.subject | Drugs | en_AU |
dc.subject | Diseases | en_AU |
dc.subject | Aging | en_AU |
dc.subject | Emission computed tomography | en_AU |
dc.title | Novel fluorinated 8-hydroxyquinoline based metal Ionophores for exploring the metal hypothesis of alzheimer’s disease | en_AU |
dc.type | Journal Article | en_AU |
dc.date.statistics | 2020-03-20 | - |
Appears in Collections: | Journal Articles |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.